Home LiteratureArticle Details
PMID: 8377152 Published · ppublish English Journal Article Review

New concepts for the control of tuberculosis in the twenty first century.

Journal of the Royal College of Physicians of London ·Vol. 27 ·No. 3 ·1993-07-00 ·Pages 218-23

Stanford JL, Grange JM

Abstract

As the end of the twentieth century approaches new methods are needed for the treatment and control of tuberculosis. Vaccination needs to be rethought, and BCG either improved or replaced. Chemotherapy is no longer enough to meet the needs of impoverished countries, non-compliant patients, and increasingly drug-resistant organisms. The next major step forward should logically come from immunology. Following the clear differentiation of two pathways of cellular immune response to mycobacterial challenge, and the recent description of two functional types of helper T cells, ideas of what controls them have allowed the logical development of a potential new vaccine and a new immunotherapy. These are based on a killed environmental organism, Mycobacterium vaccae NCTC 11659. With this simple preparation together with chemotherapy we may be armed as never before to face the inevitable challenge that tuberculosis will present to the twenty first century. Parallels recognised between cell death in tuberculosis and infection with the human immunodeficiency virus open the possibility that the progress made in immunotherapy in tuberculosis might be applicable to HIV. If this proves the case then we may also have control over the latest, and worst, risk factor for tuberculosis at the time we need it most.

MeSH Terms
BCG Vaccine Drug Resistance, Microbial Humans Immunotherapy Tuberculosis/drug therapy,prevention & control,therapy Vaccination
Chemicals
BCG Vaccine
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Stanford J L
University College London Medical School.
Grange J M
References (26)
26 references, click to expand
  1. Immunotherapy for drug-resistant tuberculosis.
    Lancet. 1992 Nov 28;340(8831):1360-1 PMID: 1360082
  2. The mystery of the mycobacterial 'persistor'.
    Tuber Lung Dis. 1992 Oct;73(5):249-51 PMID: 1493231
  3. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review.
    Tuber Lung Dis. 1992 Oct;73(5):252-61 PMID: 1493232
  4. Tuberculosis: commentary on a reemergent killer.
    Science. 1992 Aug 21;257(5073):1055-64 PMID: 1509256
  5. Koch's phenomenon: can it be corrected?
    Tubercle. 1991 Dec;72(4):241-9 PMID: 1811354
  6. Treatment of tuberculosis by private general practitioners in India.
    Tubercle. 1991 Dec;72(4):284-90 PMID: 1811360
  7. Cytokines and the Koch phenomenon.
    Tubercle. 1991 Mar;72(1):13-20 PMID: 1882441
  8. The Koch phenomenon and delayed hypersensitivity: 1891-1991.
    Tubercle. 1991 Mar;72(1):7-11 PMID: 1882447
  9. Tuberculosis and the acquired immune deficiency syndrome.
    J Appl Bacteriol. 1991 Jul;71(1):19-30 PMID: 1894579
  10. Improving on BCG.
    APMIS. 1991 Feb;99(2):103-13 PMID: 2001276
  11. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis.
    Vaccine. 1990 Dec;8(6):525-30 PMID: 2087873
  12. Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae.
    Tubercle. 1990 Dec;71(4):259-66 PMID: 2267679
  13. A pilot study of three potential vaccines for leprosy in Bombay.
    Int J Lepr Other Mycobact Dis. 1989 Mar;57(1):33-7 PMID: 2659699
  14. Vaccination and skin test studies on the children of leprosy patients.
    Int J Lepr Other Mycobact Dis. 1989 Mar;57(1):38-44 PMID: 2659700
  15. Stress proteins are immune targets in leprosy and tuberculosis.
    Proc Natl Acad Sci U S A. 1988 Jun;85(12):4267-70 PMID: 3132709
  16. The secreted antigens of Mycobacterium tuberculosis and their relationship to those recognized by the available antibodies.
    J Gen Microbiol. 1988 Feb;134(2):531-8 PMID: 3139828
  17. Suppressor determinants of mycobacteria and their potential relevance to leprosy.
    Lepr Rev. 1986 Jun;57(2):147-57 PMID: 3747706
  18. The meaning and structure of species as applied to mycobacteria.
    Tubercle. 1974 Jun;55(2):143-52 PMID: 4220078
  19. BCG vaccination of children against leprosy: nine-year findings of the controlled WHO trial in Burma.
    Bull World Health Organ. 1974;51(1):93-9 PMID: 4281729
  20. Trial of BCG vaccines in south India for tuberculosis prevention.
    Indian J Med Res. 1979 Sep;70:349-63 PMID: 535944
  21. B.C.G. vaccination of children against leprosy: first results of a trial in Uganda.
    Br Med J. 1966 Jan 1;1(5478):7-14 PMID: 5900912
  22. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis.
    Am Rev Respir Dis. 1966 Oct;94(4):553-68 PMID: 5924215
  23. How environmental mycobacteria may predetermine the protective efficacy of BCG.
    Tubercle. 1981 Mar;62(1):55-62 PMID: 7268920
  24. A TH1-->TH2 switch is a critical step in the etiology of HIV infection.
    Immunol Today. 1993 Mar;14(3):107-11 PMID: 8096699
  25. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2-microglobulin in HIV-1-associated tuberculosis.
    J Infect Dis. 1993 Jan;167(1):43-8 PMID: 8418182
  26. Chemoprophylaxis for tuberculosis.
    Respir Med. 1993 Feb;87(2):81-3 PMID: 8497689
Article Info
Journal
Journal of the Royal College of Physicians of London
Abbr.
J R Coll Physicians Lond
ISSN
0035-8819
Published
1993-07-00
Pages
218-23
Language
English
Region
England
NLM ID
7503108
PMCID
PMC5396745
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com